as 07-26-2024 4:00pm EST
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Founded: | 2020 | Country: | United States |
Employees: | N/A | City: | LAKEWAY |
Market Cap: | 54.8M | IPO Year: | 2021 |
Target Price: | $6.67 | AVG Volume (30 days): | 3.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.37 | EPS Growth: | N/A |
52 Week Low/High: | $1.62 - $4.05 | Next Earning Date: | 09-18-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ANEB Breaking Stock News: Dive into ANEB Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
GlobeNewswire
a month ago
Business Wire
2 months ago
Simply Wall St.
3 months ago
Business Wire
5 months ago
Business Wire
6 months ago
Zacks
6 months ago
GlobeNewswire
6 months ago
The information presented on this page, "ANEB Anebulo Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.